Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development

Current Problems in Cancer

Volumn 33, Issue 2, 2009, Pages 73-111

  Mahalingam, Devalingam ^a   Mita, Alain ^a   Mita, Monica M ^a   Nawrocki, Steffan T ^b   Giles, Francis J ^b  

^a University of Texas Health Science Center at San Antonio   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AMG 479; AMG 655; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CP 751871; DOCETAXEL; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PANITUMUMAB; PEMETREXED; R 1507; SCH 717454; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VORINOSTAT;

ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ANOREXIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GRANULOCYTOPENIA; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; KIDNEY CARCINOMA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; META ANALYSIS; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PROGNOSIS; PROTEINURIA; SKIN TOXICITY; SOMATIC MUTATION; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BAYES THEOREM; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; HISTONE DEACETYLASES; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHYSICIAN'S PRACTICE PATTERNS; PROTEIN-TYROSINE KINASES; RADIOTHERAPY, ADJUVANT; RECEPTOR, IGF TYPE 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65349126332     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2009.03.001     Document Type: Article

References (151)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Travis W.D. Pathology of lung cancer. Clin Chest Med 23 (2002) 65-81 viii
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
4. Payne D.G. Non-small-cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy?. J Clin Oncol 6 (1988) 552-558
5. Marino P., Preatoni A., and Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76 (1995) 593-601
6. Dillman R.O., Herndon J., Seagren S.L., Eaton Jr. W.L., and Green M.R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
7. Sause W.T., Scott C., Taylor S., Johnson D., Livingston R., Komaki R., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87 (1995) 198-205
8. Zatloukal P., Petruzelka L., Zemanova M., Havel L., Janku F., Judas L., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46 (2004) 87-98
9. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
10. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311 (1995) 899-909
11. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15 (1997) 2996-3018
12. Kosmidis P., Mylonakis N., Nicolaides C., Kalophonos C., Samantas E., Boukovinas J., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20 (2002) 3578-3585
13. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 (2001) 3210-3218
14. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
15. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18 (2007) 317-323
16. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21 (2003) 3016-3024
17. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., and Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 3852-3859
18. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (2008) 3543-3551
19. Socinski M.A., and Stinchcombe T.E. Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. J Clin Oncol 25 (2007) 5155-5157
20. Lustberg M.B., and Edelman M.J. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol 8 (2007) 38-46
21. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
22. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18 (2000) 2354-2362
23. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
24. Chattopadhyay S., Moran R.G., and Goldman I.D. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6 (2007) 404-417
25. Di Maio M., Perrone F., Chiodini P., Gallo C., Camps C., Schuette W., et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 1377-1382
26. Bria E., Cuppone F., Ciccarese M., Nistico C., Facciolo F., Milella M., et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 32 (2006) 583-587
27. Jussila L., and Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 82 (2002) 673-700
28. Homsi J., and Daud A.I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 14 (2007) 285-294
29. Miller K.D., Sweeney C.J., and Sledge Jr. G.W. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19 (2001) 1195-1206
30. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
31. O'Byrne K.J., Koukourakis M.I., Giatromanolaki A., Cox G., Turley H., Steward W.P., et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82 (2000) 1427-1432
32. Han H., Silverman J.F., Santucci T.S., Macherey R.S., d'Amato T.A., Tung M.Y., et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8 (2001) 72-79
33. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
34. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
35. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
36. Manegold C., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., Leighl N., et al. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 25 suppl (2007) LBA7514
37. Langer C.J., and Mehta M.P. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23 (2005) 6207-6219
38. Akerley W.L., Hainsworth J., Oh Y., Strickland D., Royer-Joo S., Zhou X., et al. Safety of bevacizumab therapy in subjects with brain metastases due to non-small cell lung cancer (NSCLC). J Thorac Oncol 2 (2007) S467 S
39. Liu B., Barrett T., Choyke P., Maynard K., Wright J., Kummar S., et al. A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 suppl (2006) 17119
40. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
41. Reck M., Miller V.A., Gatzemeier U., Fuhr H., Lanzalone S., Lechuga M.J., et al. A phase I dose escalation study of sunitinib in combination with gemcitabine + cisplatin for advanced non-small cell lung cancer (NSCLC). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 suppl (2007) 18057
42. Socinski M.A., Novello S., Brahmer J.R., Rosell R., Sanchez J.M., Belani C.P., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26 (2008) 650-656
43. Laurie S.A., Gauthier I., Arnold A., Shepherd F.A., Ellis P.M., Chen E., et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the national cancer institute of Canada clinical trials group. J Clin Oncol 26 (2008) 1871-1878
44. Goss G., Shepherd F.A., Laurie S., Gauthier I., Leighl N., Chen E., et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 45 (2009) 782-788
45. Chu Q.S. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Exp Opin Biol Ther 9 (2009) 263-271
46. Massarelli E., Leighl N.B., Rosen P.J., Albain K.S., Hart L.L., et al. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA). 2007 ASCO Annual Meeting Proceedings. VAM. J Clin Oncol 25 suppl (2007) 7627
47. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., and Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3 (1997) 515-522
48. Veale D., Kerr N., Gibson G.J., Kelly P.J., and Harris A.L. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68 (1993) 162-165
49. Carpenter G., and Cohen S. Epidermal growth factor. J Biol Chem 265 (1990) 7709-7712
50. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
51. Jung Y.D., Nakano K., Liu W., Gallick G.E., and Ellis L.M. Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res 59 (1999) 4804-4807
52. Ellis L.M. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 18 (2004) 1007-1021
53. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). [corrected]. J Clin Oncol 21 (2003) 2237-2246
54. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 (2004) 3238-3247
55. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
56. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
57. Niho S., Ichinose Y., Tamura T., Yamamoto N., Tsuboi M., Nakagawa K., et al. Results of a randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 suppl (2007) LBA7509
58. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372 (2008) 1809-1818
59. Bezjak A., Tu D., Seymour L., Clark G., Trajkovic A., Zukin M., et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24 (2006) 3831-3837
60. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
61. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
62. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
63. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25 (2007) 1545-1552
64. Solit D.B., She Y., Lobo J., Kris M.G., Scher H.I., Rosen N., et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 11 (2005) 1983-1989
65. Lee J.S., Ignacio J., Yu C., Zhou C., Wu Y., Chen Y., et al. FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 26 suppl (2008) abstr 8031
66. Hanna N., Lilenbaum R., Ansari R., Lynch T., Govindan R., Janne P.A., et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24 (2006) 5253-5258
67. Kim E.S., Mauer A.M., Tran H.T., Liu D., Gladish G., Dicke K., et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc Am Soc Clin Oncol 22 (2003) abstr 2581
68. Robert F., Blumenschein G., Herbst R.S., Fossella F.V., Tseng J., Saleh M.N., et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 9089-9096
69. Thienelt C.D., Bunn P.A., Hanna N., Rosenberg A., Needle M.N., Long M.E., et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23 (2005) 8786-8793
70. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19 (2008) 362-369
71. Blumenschein G.R., Paulus R., Curran W.J., Robert F., Fossella F.V., Werner-Wasik M., et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. Clin Oncol 26 suppl (2008) abstr 7516
72. Crawford J., Swanson P., Prager D., Schwarzenberger P., Sandler A., Schiller J., et al. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis. Ejc Suppl 3 (2005) 324
73. Riely G.J., Politi K.A., Miller V.A., and Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12 (2006) 7232-7241
74. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
75. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
76. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004) 13306-13311
77. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 (2006) 3340-3346
78. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
79. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 (2005) 5900-5909
80. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Jaenne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26 (2008) 2442-2449
81. Costa D.B., Kobayashi S., Tenen D.G., and Huberman M.S. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58 (2007) 95-103
82. Cappuzzo F., Gregorc V., Rossi E., Cancellieri A., Magrini E., Paties C.T., et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21 (2003) 2658-2663
83. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
84. Hirsch F.R., Varella-Garcia M., Dziadziuszko R., Xiao Y., Gajapathy S., Skokan M., et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res 14 (2008) 6317-6323
85. Ahrendt S.A., Decker P.A., Alawi E.A., Zhu Yr Y.R., Sanchez-Cespedes M., Yang S.C., et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92 (2001) 1525-1530
86. Slebos R.J., Hruban R.H., Dalesio O., Mooi W.J., Offerhaus G.J., and Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 83 (1991) 1024-1027
87. Roberts P.J., and Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 (2007) 3291-3310
88. Shields J.M., Pruitt K., McFall A., Shaub A., and Der C.J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 10 (2000) 147-154
89. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 (2005) 857-865
90. Han S.W., Kim T.Y., Jeon Y.K., Hwang P.G., Im S.A., Lee K.H., et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12 (2006) 2538-2544
91. Zhu C.Q., Santos G.D., Ding K., Sakurada A., Cutz J.C., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR. 21. J Clin Oncol 26 (2008) 4268-4275
92. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13 (2007) 2890-2896
93. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12 (2006) 5764-5769
94. Costa D.B., Nguyen K.S.H., Cho Y.C., Sequist L.V., Jackman D.M., Riely G., et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 14 (2008) 7060-7067
95. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104 (2007) 20932-20937
96. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
97. Taguchi F., Solomon B., Gregorc V., Roder H., Gray R., Kasahara K., et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 99 (2007) 838-846
98. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
99. Saltz L.B., Lenz H.J., Kindler H.L., Hochster H.S., Wadler S., Hoff P.M., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25 (2007) 4557-4561
100. Herbst R.S., Johnson D.H., Mininberg E., Carbone D.P., Henderson T., Kim E.S., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 2544-2555
101. Herbst R.S., O'Neill V.J., Fehrenbacher L., Belani C.P., Bonomi P.D., Hart L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25 (2007) 4743-4750
102. Heymach J.V., Paz-Ares L., De Braud F., Sebastian M., Stewart D.J., Eberhardt W.E.E., et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26 (2008) 5407-5415
103. Sachdev D., and Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6 (2007) 1-12
104. Clemmons D.R. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev 6 (2007) 821-833
105. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., and Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91 (1999) 151-156
106. Valentinis B., and Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 54 (2001) 133-137
107. Gualberto A., Melvin C.L., Dean A., Ang A.L., Reynolds J.M., Lee A.V., et al. Characterization of NSCLC patients responding to anti-IGF-IR therapy. Clin Oncol 26 suppl (2008) abstr 8000
108. Rodon J., DeSantos V., Ferry Jr. R.J., and Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7 (2008) 2575-2588
109. Karp D.D., Paz-Ares L.G., Novello S., Haluska P., Garland L., Cardenal F., et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. J Clin Oncol 26 suppl (2008) abstr 8015
110. Knowlden J.M., Jones H.E., Barrow D., Gee J.M., Nicholson R.I., and Hutcheson I.R. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat 111 (2008) 79-91
111. Morgillo F., Kim W.Y., Kim E.S., Ciardiello F., Hong W.K., and Lee H.Y. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13 (2007) 2795-2803
112. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
113. Tschoep K., Kohlmann A., Schlemmer M., Haferlach T., and Issels R.D. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 63 (2007) 111-124
114. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4 (2005) 988-1004
115. Mamane Y., Petroulakis E., Rong L., Yoshida K., Ler L.W., and Sonenberg N. eIF4E-from translation to transformation. Oncogene 23 (2004) 3172-3179
116. Holz M.K., Ballif B.A., Gygi S.P., and Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123 (2005) 569-580
117. Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 (2004) 200-205
118. Marsit C.J., Zheng S., Aldape K., Hinds P.W., Nelson H.H., Wiencke J.K., et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 36 (2005) 768-776
119. Soria J.C., Lee H.Y., Lee J.I., Wang L., Issa J.P., Kemp B.L., et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8 (2002) 1178-1184
120. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65 (2005) 7591-7595
121. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
122. Milton D.T., Riely G.J., Azzoli C.G., Gomez J.E., Heelan R.T., Kris M.G., et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110 (2007) 599-605
123. Kris M.G., Riely G.J., Azzoli C.G., Heelan R.T., Krug L.M., Pao W., et al. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: a phase II trial. 2007 ASCO Annual Meeting Proceedings J Clin Oncol 25 suppl (2007) 7575
124. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nature Rev 5 (2006) 769-784
125. Carew J.S., Giles F.J., and Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269 (2008) 7-17
126. Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S., et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. The EMBO J 22 (2003) 1168-1179
127. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97 (2000) 10014-10019
128. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18 (2007) 769-774
129. Sasaki H., Moriyama S., Nakashima Y., Kobayashi Y., Kiriyama M., Fukai I., et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 46 (2004) 171-178
130. Loprevite M., Tiseo M., Grossi F., Scolaro T., Semino C., Pandolfi A., et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res 15 (2005) 39-48
131. Cuneo K.C., Fu A., Osusky K., Huamani J., Hallahan D.E., and Geng L. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs 18 (2007) 793-800
132. Edwards A., Li J., Atadja P., Bhalla K., and Haura E.B. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 6 (2007) 2515-2524
133. Traynor A.M., Dubey S., Eickhoff J., Kolesar J.M., Marcotte S.M., Hammes L.C., et al. A phase II study of vorinostat (NSC 701852) in patients (pts) with relapsed non-small cell lung cancer (NSCLC). 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 25 suppl (2007) 18044
134. Reid T., Valone F., Lipera W., Irwin D., Paroly W., Natale R., et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45 (2004) 381-386
135. Ramalingam S.S., Parise R.A., Ramanathan R.K., Lagattuta T.F., Musguire L.A., Stoller R.G., et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13 (2007) 3605-3610
136. Davies A.M., Lara Jr. P.N., Mack P.C., and Gandara D.R. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13 (2007) s4647-s4651
137. Gettinger S. Targeted therapy in advanced non-small-cell lung cancer. Semin Respir Crit Care Med 29 (2008) 291-301
138. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5 (2004) 417-421
139. Denlinger C.E., Rundall B.K., Keller M.D., and Jones D.R. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 78 (2004) 1207-1214
140. Davies A.M., Ho C., Metzger A.S., Beckett L.A., Christensen S., Tanaka M., et al. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol 2 (2007) 1112-1116
141. Davies A.M., Fenton D.W., Lau D.H., Mack P.C., Gumerlock P.H., Gandara D.R., et al. The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): final results of a phase I California Cancer Consortium study. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 22 suppl (2004) 7106
142. Davies A.M., Chansky K., Lara Jr. P.N., Gumerlock P.H., Crowley J., Albain K.S., et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 4 (2009) 87-92
143. Lynch T.J., Hirsh V., Bodkin D.J., Middleman E., Chiappori A., et al. Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC). 2007 ASCO Annual Meeting Proceedings. DWF. J Clin Oncol 25 suppl (2007) 7680
144. Fanucchi M.P., Fossella F.V., Belt R., Natale R., Fidias P., Carbone D.P., et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5025-5033
145. Samali A., Gorman A.M., and Cotter T.G. Apoptosis: the story so far. Experientia 52 (1996) 933-941
146. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., et al. Human ICE/CED-3 protease nomenclature. Cell 87 (1996) 171
147. Mahalingam D., Szegezdi E., Keane M., Jong S.D., and Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL?. Cancer Treat Rev (2008) December 29
148. LoRusso P., Hong D., Heath E., Kurzrock R., Wang D., Hsu M., et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 25 suppl (2007) 3534
149. Soria J., Smit E.F., Khayat D., Besse B., Burton J., Yang X., et al. Phase Ib study of recombinant human (rh)Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26 suppl (2008) abstr 3539
150. Greco F.A., Bonomi P., Crawford J., Kelly K., Oh Y., Halpern W., et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61 (2008) 82-90
151. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360 (2009) 563-572